Plain-English translation of NCT06233461 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Crohn's Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new oral medication called to see if it can help reduce inflammation in the bowel for people with moderately to severely active Crohn's disease. Researchers want to find out whether this medication works, how safe it is, and what the best dose might be. About 268 people will participate, and some will receive the medication while others receive a placebo (a pill with no active ingredient) so researchers can compare the results.
Many people with Crohn's disease don't respond well enough to current treatments or stop responding over time. This trial exists to see if this medication could offer a new option for people whose Crohn's disease hasn't been controlled adequately by other therapies.
You likely qualify if…
You likely don't qualify if…
You would take capsules by mouth as part of the study, with visits over approximately 60 weeks. You'll be randomly assigned to receive one of three doses of the medication or a placebo, and neither you nor your study doctor will know which you're receiving (unless there's an urgent medical need). The study will include an induction period to test the medication's effects, followed by a 4-week safety follow-up period, with regular check-ins at multiple study centers worldwide to monitor how you're doing and any side effects.
AI-generated summary from trial data · Sep 5, 2026 · Not medical advice
United States